| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Laboratory of Tumor Immunology and Biology, Division of Basic Science, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Prostate-specific Ag (PSA), which is expressed in a majority of prostate cancers, is a potential target for specific immunotherapy. Previous studies have shown that two 10-mer PSA peptides (designated PSA-1 and PSA-3) selected to conform to human HLA class I-A2 motifs can elicit CTL responses in vitro. A longer PSA peptide (30-mer) designated PSA-OP (oligoepitope peptide), which contains both the PSA-1 and PSA-3 HLA-A2 epitopes and an additional potential CTL epitope (designated PSA-9) for the HLA-class I-A3 allele, was investigated for the ability to induce cytotoxic T cell activity. T cell lines from different HLA-A2 and HLA-A3 donors were established by in vitro stimulation with PSA-OP; the CTL lines lysed PSA-OP as well as PSA-1- or PSA-3-pulsed C1R-A2 cells, and PSA-OP and PSA-9-pulsed C1R-A3 cells, respectively. The CTL lines derived from the PSA-OP peptide also lysed PSA-positive prostate cancer cells. PSA-OP-derived T cell lines also lysed recombinant vaccinia-PSA-infected targets but not targets infected with wild-type vaccinia. PSA-OP did not bind HLA-A2 and HLA-A3 molecules. The decrease in cytotoxicity in the presence of protease inhibitors suggests that the PSA-OP is cleaved into shorter peptides, which in turn can interact with HLA-class I molecules and, as a consequence, induce CTL-mediated lysis. We have also demonstrated that it is possible to induce CTL responses in HLA-A2.1/Kb transgenic mice by immunization with PSA-OP with adjuvant. These studies thus provide evidence that oligopeptides such as PSA-OP may be useful candidates for peptide-based cancer vaccines.
This article has been cited by other articles:
|
|
 |
|
  C. Domschke, F. Schuetz, Y. Ge, T. Seibel, C. Falk, B. Brors, I. Vlodavsky, N. Sommerfeldt, H.-P. Sinn, M.-C. Kuhnle, et al. Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer-Specific Immune Responses and Their Correlation to Prognosis Cancer Res., November 1, 2009; 69(21): 8420 - 8428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sommerfeldt, F. Schutz, C. Sohn, J. Forster, V. Schirrmacher, and P. Beckhove The Shaping of a Polyvalent and Highly Individual T-Cell Repertoire in the Bone Marrow of Breast Cancer Patients Cancer Res., August 15, 2006; 66(16): 8258 - 8265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Arlen, J. L. Gulley, C. Parker, L. Skarupa, M. Pazdur, D. Panicali, P. Beetham, K. Y. Tsang, D. W. Grosenbach, J. Feldman, et al. A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus Vaccine Alone in Metastatic Androgen-Independent Prostate Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1260 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P.F. Gade, W. Hassen, E. Santos, G. Gunset, A. Saudemont, M. C. Gong, R. Brentjens, X.-S. Zhong, M. Stephan, J. Stefanski, et al. Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes Cancer Res., October 1, 2005; 65(19): 9080 - 9088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matsueda, H. Takedatsu, A. Yao, M. Tanaka, M. Noguchi, K. Itoh, and M. Harada Identification of Peptide Vaccine Candidates for Prostate Cancer Patients with HLA-A3 Supertype Alleles Clin. Cancer Res., October 1, 2005; 11(19): 6933 - 6943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Gulley, P. M. Arlen, A. Bastian, S. Morin, J. Marte, P. Beetham, K.-Y. Tsang, J. Yokokawa, J. W. Hodge, C. Menard, et al. Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer Clin. Cancer Res., May 1, 2005; 11(9): 3353 - 3362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Kaufman, W. Wang, J. Manola, R. S. DiPaola, Y.-J. Ko, C. Sweeney, T. L. Whiteside, J. Schlom, G. Wilding, and L. M. Weiner Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group J. Clin. Oncol., June 1, 2004; 22(11): 2122 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oh, M. Terabe, C. D. Pendleton, A. Bhattacharyya, T. K. Bera, M. Epel, Y. Reiter, J. Phillips, W. M. Linehan, C. Kasten-Sportes, et al. Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells Cancer Res., April 1, 2004; 64(7): 2610 - 2618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takedatsu, S. Shichijo, K. Katagiri, H. Sawamizu, M. Sata, and K. Itoh Identification of Peptide Vaccine Candidates Sharing among HLA-A3+, -A11+, -A31+, and -A33+ Cancer Patients Clin. Cancer Res., February 1, 2004; 10(3): 1112 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gnjatic, D. Atanackovic, M. Matsuo, E. Jager, S. Y. Lee, D. Valmori, Y.-T. Chen, G. Ritter, A. Knuth, and L. J. Old Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs J. Immunol., February 1, 2003; 170(3): 1191 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Herness and R. K. Naz A Novel Human Prostate-specific Gene-1 (HPG-1): Molecular Cloning, Sequencing, and Its Potential Involvement in Prostate Carcinogenesis Cancer Res., January 15, 2003; 63(2): 329 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lu and E. Celis Recognition of Prostate Tumor Cells by Cytotoxic T Lymphocytes Specific for Prostate-specific Membrane Antigen Cancer Res., October 15, 2002; 62(20): 5807 - 5812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Alexander, C. Oseroff, C. Dahlberg, M. Qin, G. Ishioka, M. Beebe, J. Fikes, M. Newman, R. W. Chesnut, P. A. Morton, et al. A Decaepitope Polypeptide Primes for Multiple CD8+ IFN-{gamma} and Th Lymphocyte Responses: Evaluation of Multiepitope Polypeptides as a Mode for Vaccine Delivery J. Immunol., June 15, 2002; 168(12): 6189 - 6198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Terasawa, K.-Y. Tsang, J. Gulley, P. Arlen, and J. Schlom Identification and Characterization of a Human Agonist Cytotoxic T-Lymphocyte Epitope of Human Prostate-specific Antigen Clin. Cancer Res., January 1, 2002; 8(1): 41 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Miyagi, N. Imai, T. Sasatomi, A. Yamada, T. Mine, K. Katagiri, M. Nakagawa, A. Muto, S. Okouchi, H. Isomoto, et al. Induction of Cellular Immune Responses to Tumor Cells and Peptides in Colorectal Cancer Patients by Vaccination with SART3 Peptides Clin. Cancer Res., December 1, 2001; 7(12): 3950 - 3962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yamada, K. Kawano, M. Koga, T. Matsumoto, and K. Itoh Multidrug Resistance-associated Protein 3 Is a Tumor Rejection Antigen Recognized by HLA-A2402-restricted Cytotoxic T Lymphocytes Cancer Res., September 1, 2001; 61(17): 6459 - 6466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. McNeel, L. D. Nguyen, and M. L. Disis Identification of T Helper Epitopes from Prostatic Acid Phosphatase Cancer Res., July 1, 2001; 61(13): 5161 - 5167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tsavaler, M. H. Shapero, S. Morkowski, and R. Laus Trp-p8, a Novel Prostate-specific Gene, Is Up-Regulated in Prostate Cancer and Other Malignancies and Shares High Homology with Transient Receptor Potential Calcium Channel Proteins Cancer Res., May 1, 2001; 61(9): 3760 - 3769. [Abstract] [Full Text]
|
|
|
|
|
|
M. Nouri-Shirazi, J. Banchereau, D. Bell, S. Burkeholder, E. T. Kraus, J. Davoust, and K. A. Palucka Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Responses J. Immunol., October 1, 2000; 165(7): 3797 - 3803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nishizaka, S. Gomi, K. Harada, K. Oizumi, K. Itoh, and S. Shichijo A New Tumor-Rejection Antigen Recognized by Cytotoxic T Lymphocytes Infiltrating into a Lung Adenocarcinoma Cancer Res., September 1, 2000; 60(17): 4830 - 4837. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kawano, S. Gomi, K. Tanaka, N. Tsuda, T. Kamura, K. Itoh, and A. Yamada Identification of a New Endoplasmic Reticulum-resident Protein Recognized by HLA-A24-restricted Tumor-infiltrating Lymphocytes of Lung Cancer Cancer Res., July 1, 2000; 60(13): 3550 - 3558. [Abstract] [Full Text]
|
|
|
|
|
|
A. Heiser, P. Dahm, D. R. Yancey, M. A. Maurice, D. Boczkowski, S. K. Nair, E. Gilboa, and J. Vieweg Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro J. Immunol., May 15, 2000; 164(10): 5508 - 5514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Eder, P. W. Kantoff, K. Roper, G. Xu, G. J. Bubley, J. Boyden, L. Gritz, G. Mazzara, W. K. Oh, P. Arlen, et al. A Phase I Trial of a Recombinant Vaccinia Virus Expressing Prostate-specific Antigen in Advanced Prostate Cancer Clin. Cancer Res., May 1, 2000; 6(5): 1632 - 1638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nakao, S. Shichijo, T. Imaizumi, Y. Inoue, K. Matsunaga, A. Yamada, M. Kikuchi, N. Tsuda, K. Ohta, S. Takamori, et al. Identification of a Gene Coding for a New Squamous Cell Carcinoma Antigen Recognized by the CTL J. Immunol., March 1, 2000; 164(5): 2565 - 2574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gomi, M. Nakao, F. Niiya, Y. Imamura, K. Kawano, S. Nishizaka, A. Hayashi, Y. Sobao, K. Oizumi, and K. Itoh A Cyclophilin B Gene Encodes Antigenic Epitopes Recognized by HLA-A24-Restricted and Tumor-Specific CTLs J. Immunol., November 1, 1999; 163(9): 4994 - 5004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Simons, B. Mikhak, J.-F. Chang, A. M. DeMarzo, M. A. Carducci, M. Lim, C. E. Weber, A. A. Baccala, M. A. Goemann, S. M. Clift, et al. Induction of Immunity to Prostate Cancer Antigens: Results of a Clinical Trial of Vaccination with Irradiated Autologous Prostate Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-stimulating Factor Using ex Vivo Gene Transfer Cancer Res., October 1, 1999; 59(20): 5160 - 5168. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
